FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab

Iravani, A; Wallace, R; Lo, SN; Galligan, A; Weppler, AM; Hicks, RJ; Sandhu, S

Author(s): Iravani, A; Wallace, R; Lo, SN; Galligan, A; Weppler, AM; Hicks, RJ; Sandhu, S;
Details: Publication Year 2023-05,Volume 307,Issue #3,Page e221180
Journal Title: Radiology
Publication Type: Research article
Abstract: Background Despite improved response to combined ipilimumab and nivolumab (hereafter, IpiNivo) treatment for advanced melanoma, many patients exhibit primary or acquired resistance. This, combined with high risk of immune-related adverse events, makes identifying markers predictive of outcomes desirable. Purpose To investigate the prognostic value of fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT parameters at baseline and as part of response monitoring in patients with advanced melanoma undergoing IpiNivo treatment. Materials and Methods This was a single-center retrospective study of adult patients with melanoma who received IpiNivo. Baseline FDG PET/CT parameters that included metabolic tumor volume (MTV), tumor stage, mutation status, Eastern Cooperative Oncology Group performance score, lactate dehydrogenase level, and treatment line were correlated with overall survival in univariable and multivariable Cox regression analyses. Treatment response as determined with FDG PET/CT was correlated with overall survival. Results In total, 122 patients (median age, 61 years [IQR, 51-69 years]; 89 men) were included; 78% (95 of 122) had an Eastern Cooperative Oncology Group score of 0, 52% (45 of 86) had an elevated lactate dehydrogenase level, 39% (48 of 122) had a metastatic stage of M1c and 45% (55 of 122) M1d, 45% (55 of 122) had BRAF V600E/K mutation, and the median MTV was 42 mL. Patients with a higher than median MTV at baseline FDG PET/CT had a lower 12-month survival rate compared with those with a lower than median MTV (43% [95% CI: 32, 58] vs 66% [95% CI: 55, 79], P < .001). In multivariable analysis, higher versus lower than median MTV, Eastern Cooperative Oncology Group performance scores of 1-2 versus 0, and subsequent versus first-line IpiNivo treatment were independently associated with overall survival (hazard ratio [HR]: 1.68 [95% CI: 1.02, 2.78], P = .04; 3.1 [95% CI: 1.8, 5.4], P < .001; and 11.2 [95% CI: 3.4, 37.1], P = .002, respectively). The 12-month overall survival rate was lower in patients with progressive disease than in those without progression (35% [95% CI: 24, 51] vs 90% [95% CI: 83, 99]; HR, 7.3 [95% CI: 3.9, 13.3]; P < .001). Conclusion Baseline fluorine 18 fluorodeoxyglucose PET/CT metabolic tumor volume was an independent prognostic marker in patients with advanced melanoma who received ipilimumab and nivolumab treatment. (c) RSNA, 2023 Supplemental material is available for this article.
Publisher: Radiological Society of North America
Keywords: Male; Adult; Humans; Middle Aged; Ipilimumab; *Positron Emission Tomography Computed Tomography; Fluorodeoxyglucose F18; Nivolumab; Prognosis; Retrospective Studies; *Melanoma/pathology; Lactate Dehydrogenases; Tumor Burden
Department(s): Cancer Imaging; Medical Oncology
PubMed ID: 36853183
Publisher's Version: https://doi.org/10.1148/radiol.221180
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-08-15 07:31:27

Last Modified: 2024-07-09 05:34:22